Pharmaceutical Science cmte. heads down “Critical Path”
FDA's Advisory Committee for Pharmaceutical Science will discuss "Critical Path" initiative research opportunities on the first day if its Oct. 19-20 meeting. On Oct. 20, the committee will discuss implementation of the risk-based GMP initiative and generic drug equivalence issues. The meeting will be held at the CDER Advisory Committee conference room, 5630 Fishers Lane in Rockville, Md. beginning at 8:30 a.m. both days. [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”